



RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

Complete if Known

Application Number	09/935,168 TECH CENTER 1600
Filing Date	August 21, 2001
First Named Inventor	Jennifer L. West
Group Art Unit	1645 1644
Examiner Name	
Attorney Docket Number	RICE 103

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

[illegible][illegible]

Examine Signature		Date Considered	11/21/02
-------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0501-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/935,168
		Filing Date	August 21, 2001
		First Named Inventor	Jennifer L. West
		Group Art Unit	1645 1644
		Examiner Name	
Sheet 3	3	Attorney Docket Number	RICE 103

RECEIVED
AUG 06 2002
TECH CENTER 1800/2900

O I P E
AUG 05 2002
PATENT & TRADEMARK OFFICE

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JWA		NABEL, et al., "Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia" <i>Proc. Natl. Acad. Sci. USA</i> 90(22):10759-10763 (1993).	
		NICOLL, et al., "In vitro characterization of transforming growth factor-beta-1-loaded composites of biodegradable polymer and mesenchymal cells" <i>Cells and Materials</i> 5(3): 231-244 (1995).	
		PANDIT, et al., "The effect of TGF-beta delivered through a collagen scaffold on wound healing" <i>J. Invest. Surg.</i> 12(2):89-100 (1999).	
		PLENZ, et al., "Colony stimulating factors modulate the transcription of type VIII collagen in vascular smooth muscle cells" <i>Atherosclerosis</i> 144(1):25-32 (1999).	
		PUOLAKKAINEN, et al., "The enhancement in wound healing by transforming growth factor-beta 1 (TGF-beta 1) depends on the topical delivery system" <i>J. Surg. Res.</i> 58(3):321-329 (1995).	
		SCHROEDER-TEFFT, et al., "Collagen and heparin matrices for growth factor delivery" <i>Journal of Controlled Release</i> 49(2-3): 291-298 (1997).	
		SCOTT-BURDEN, et al., "Epidermal growth factor responsiveness in smooth muscle cells from hypertensive and normotensive rats" <i>Hypertension</i> 13(4):295-305 (1989).	
		TONG et al., "Peptide surface modification of poly(tetrafluoroethylene-co-hexafluoropropylene) enhances its interaction with central nervous system neurons" <i>J. Biomed. Mater. Res.</i> 42(1):85-95 (1998)	
		WOESSNER, et al., "The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid" <i>Arch. Biochem. Biophys.</i> 93:440-447 (1961).	
✓		ZHANG, et al., "Biological surface engineering: a simple system for cell pattern formation" <i>Biomaterials</i> 20(13):1213-1220 (1999).	

Examiner's Signature	<i>[Signature]</i>	Date Considered	11/21/02
----------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RECEIVED

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/935,168
		Filing Date	August 21, 2001
		First Named Inventor	Jennifer L. West
		Group Art Unit	1645 1644
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	RICE 103	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
PWK		AMENTO, et al., "Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells" <i>Arterioscler. Thromb.</i> 11(5):1223-1230 (1991).	
		CLARK, et al., "Collagen matrices attenuate the collagen-synthetic response of cultured fibroblasts to TGF-beta" <i>J. Cell Sci.</i> 108(Pt3):1251-1261 (1995).	
		DEE, et al., "Design and function of novel osteoblast-adhesive peptides for chemical modification of biomaterials" <i>J. Biomed. Mater. Res.</i> 40(3):371-377 (1998).	
		EICKELBERG, et al., "Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3" <i>Am. J. Physiol.</i> 276(5 Pt 1):L814-L824 (1999).	
		HEIMER, et al., "TGF-beta modulates the synthesis of proteoglycans by myocardial fibroblasts in culture" <i>J. Mol. Cell Cardiol.</i> 27(10):2191-2198 (1995).	
		HERN et al., "Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing" <i>J. Biomed. Mater. Res.</i> 39(2):266-276 (1998).	
		JONES, et al., "Glycoprotein, elastin, and collagen secretion by rat smooth muscle cells" <i>Proc. natl. Acad. Sci. USA</i> 76(1):353-357 (1979).	
		LAWRENCE, et al., "Transforming growth factor beta 1 stimulates type V collagen expression in bovine vascular smooth muscle cells" <i>J. Biol. Chem.</i> 269:9603-9609 (1994).	
		MAJESKY, et al., "Production of transforming growth factor beta 1 during repair of arterial injury" <i>J. Clin. Invest.</i> 88(3):904-910 (1991).	
		MANN, et al., "Modification of surfaces with cell adhesion peptides alters extracellular matrix deposition" <i>Biomaterials</i> 20(23-24):2281-2286 (1999).	
		MASSIA et al., "Covalent surface immobilization of Arg-Gly-Asp- and Tyr-Ile-Gly-Ser-Arg-containing peptides to obtain well-defined cell-adhesive substrates" <i>Anal. Biochem.</i> 187(2):292-301 (1990).	

Examiner's Signature	<i>Phyllis N. S...</i>	Date Considered	11/21/02
----------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



**COPY OF PAPERS
ORIGINALLY FILED**

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED
AUG 09 2002
TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number 09/935,168

Filing Date August 21, 2001

First Named Inventor Jennifer L. West

Group Art Unit 1645

Examiner Name

Attorney Docket Number RICE 103

Sheet 1 of 1

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Path		HOERSTRUP, et al., "Tissue Engineering of a Bioprosthetic Heart Valve: Stimulation of Extracellular Matrix Assessed by Hydroxyproline Assay," <i>ASAIO Journal</i> 45(5): 397-402 (1999).	
Path		MANN, et al., "Tethered-TGF - Beta increases extracellular matrix production of vascular smooth muscle cells," <i>Biomaterials</i> 22(5): 439-444 (2001).	

Examiner's Signature  Date Considered 11/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.